Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy

NCT01071915 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT01071915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01071915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy
Lead sponsor
Ferring Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
November 30, 2011
Enrollment
157 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer